Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Dermatologic 2Sarcoma 1Other solid neoplasm 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Melanoma 136Lymphoma, T-Cell, Cutaneous 45Lymphoma, Non-Hodgkin 37Lymphoma, Follicular 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Large-Cell, Immunoblastic 34Leukemia, Lymphocytic, Chronic, B-Cell 34Lymphoma, Mantle-Cell 33Lymphoma, B-Cell, Marginal Zone 33Burkitt Lymphoma 33Lymphoma 32Leukemia, Myeloid, Acute 32Hodgkin Disease 31Mycosis Fungoides 30Sezary Syndrome 29Multiple Myeloma 28Leukemia, Myeloid, Accelerated Phase 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 24Neoplasm Metastasis 24Leukemia, Myeloid, Chronic-Phase 24Leukemia 23Myelodysplastic Syndromes 22Lymphoma, Large-Cell, Anaplastic 22Congenital Abnormalities 22Blast Crisis 22Skin Neoplasms 20Immunoblastic Lymphadenopathy 20Myeloproliferative Disorders 19Recurrence 18

Interventions

pembrolizumab 3Nivolumab 3fludarabine 2atezolizumab 2Cyclophosphamide 2fludarabine phosphate 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Carboxylesterase 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Microsatellite Instability × Cyclophosphamide × Dermatologic × Clear all
NCT03935893 2026-06-01

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

University of Pittsburgh

Phase 2 Active not recruiting
20 enrolled
DermatologicEndocrineGastrointestinalNETOther solid neoplasmSarcomaThoracic

Turcot syndrome, Mesothelioma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Neuroendocrine Tumors, Microsatellite Instability

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡